儿童期起病狼疮中儿童糖皮质激素毒性指数的真实世界应用
在两家儿童中心1999至2023年回顾性队列中,对126例儿童期起病系统性红斑狼疮(pSLE)患者(其中88例肾炎)采用改良儿童糖皮质激素毒性指数(pGTI)每6个月评分,评估回顾性评分的可行性与结构效度并识别累积毒性危险因素;血压域毒性最常见(47%),累积糖皮质激素剂量与累积恶化评分(CWS)呈弱相关(rho 0.3;p<0.01),更年幼、基线BMI升高及启动糖皮质激素时使用利妥昔单抗与更高累积毒性相关。
要点
- 126例pSLE患者中47%出现血压域毒性,情绪障碍25%,BMI升高、紫纹、睡眠障碍各21%,生长速度下降18%。
- 累积糖皮质激素剂量与CWS弱相关(rho 0.3;p<0.01)。
- 更年幼、BMI升高及启动糖皮质激素时使用利妥昔单抗与更高累积毒性相关,但后者适应证未采集。
核心结论
- pSLE患者糖皮质激素毒性负担高,尤其涉及血压、BMI、睡眠和生长。
- 儿童特异性糖皮质激素毒性标准化评估在真实世界环境中可行,可促进评估减少需长期糖皮质激素治疗儿童 morbidity 的策略。
研究设计与样本
- 回顾性队列研究,纳入两家儿童中心1999至2023年接受糖皮质激素治疗的pSLE患者126例,其中肾炎88例,中位随访6次/人。
- 糖皮质激素暴露采用区间平均口服泼尼松等效剂量和累积泼尼松等效剂量估算。
- 采用包含10个域中7个域的改良pGTI每6个月(±2)评分毒性变化,计算累积恶化评分(CWS),并用混合效应线性回归识别与CWS相关的因素。
主要发现
- 血压域毒性发生率47%,情绪障碍25%,BMI升高、紫纹和睡眠障碍各21%,生长速度下降18%。
- 累积糖皮质激素剂量与CWS呈弱相关(rho 0.3;p<0.01)。
- 更年幼、BMI升高及启动糖皮质激素时使用利妥昔单抗与更高累积毒性相关,但利妥昔单抗适应证未采集。
局限性
- 原文为回顾性队列研究。
- 利妥昔单抗使用与更高累积毒性相关,但其适应证未被采集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: The pediatric Glucocorticoid Toxicity Index (pGTI) is a new, pediatric-specific tool to quantify glucocorticoid (GC)-related morbidity in children. We evaluated the feasibility and construct validity of retrospective pGTI scoring in patients with pediatric-onset systemic lupus erythematosus (pSLE) and identified risk factors for cumulative toxicity. METHODS: We conducted a retrospective cohort study of patients with pSLE treated with GCs at two pediatric centers (1999-2023). GC exposure was estimated using interval-averaged oral prednisone-equivalent dose and cumulative prednisone-equivalent dose. We scored change in GC toxicity every 6 months (±2) using a modified pGTI including 7 of 10 domains. We calculated the Cumulative Worsening Score (CWS), a continuous summation of toxicity accrued. Mixed effects linear regression was used to identify factors associated with CWS. RESULTS: There were 126 patients with pSLE, including 88 with nephritis, with a median of 6 visits/patient. Nearly half (47 %) experienced toxicity in the Blood Pressure domain. Other common toxicities were mood disturbance (25 %), followed by increased body mass index (BMI), striae, and sleep disturbance (21 % each). Decreased growth velocity was observed in 18 %. There was modest correlation between cumulative GC dose and CWS (rho 0.3; p < 0.01). Greater cumulative toxicity was associated with younger age, elevated BMI, and rituximab use at the time of GC initiation, albeit indications for the latter were not captured. CONCLUSIONS: Patients with pSLE experience a high burden of GC toxicity, particularly related to blood pressure, BMI, sleep, and growth. Standardized, pediatric-specific GC toxicity assessment is feasible in real-world settings and can facilitate evaluation of strategies to reduce morbidity in children requiring chronic GC treatment.
引用
- Zhang E, Capponi S, Scobell R, et al. Real-world application of the pediatric Glucocorticoid Toxicity Index in childhood-onset lupus. Semin Arthritis Rheum. 2024. PMID: 39059156. doi:10.1016/j.semarthrit.2024.152516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。